EGFR Antibody Combined With PD-1 Inhibitor and Chemotherapy in R/M Nasopharyngeal Carcinoma

Summary

This is a prospective, single-arm, phase II clinical trial. The purpose of this study is to evaluate the efficacy and adverse effect of EGFR antibody combined with programmed death 1 (PD-1) antibody and chemotherapy in recurrent/metastatic nasopharyngeal carcinoma patients.

Conditions

• Nasopharyngeal Cancinoma (NPC)
• Recurrent Nasopharynx Carcinoma
• Metastatic Nasopharyngeal Carcinoma

Interventions

DRUG

PD-1 antibody

6 cycles for combined therapy. Maintenance for 1 year.

DRUG

Gemcitabine, Cisplatin

6 cycles for combined therapy.

RADIATION

IMRT

IMRT for primary lesion

DRUG

EGFR Antibody

6 cycles for combined therapy. Maintenance for 1 year.

Sponsors & Collaborators

• Zhejiang Cancer Hospital

  collaborator OTHER

• Wuhan TongJi Hospital

  collaborator OTHER

• Xijing hospital of The fourth military medical university

  collaborator UNKNOWN

• Dongguan People's Hospital

  collaborator OTHER_GOV

• Liuzhou Workers' Hospital

  collaborator OTHER_GOV

• Chongqing University Cancer Hospital

  collaborator OTHER

• Second Affiliated Hospital, School of Medicine, Zhejiang University

  collaborator OTHER

• Jiangxi Provincial Cancer Hospital

  collaborator OTHER

• Fujian Province Tumor Hospital

  collaborator OTHER

• The First Affiliate Hospital of Guangxi Medical College

  collaborator UNKNOWN

• Sun Yat-sen University

  lead OTHER

Study Design

Allocation

NA

Purpose

TREATMENT

Masking

NONE

Model

SINGLE_GROUP

Eligibility

Min Age

18 Years

Max Age

75 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2025-07-09

Primary Completion

2027-06-30

Completion

2029-06-30

Countries

• China

Study Locations